Since 2016, a group of committed multistakeholders representing public and private payers, labs, providers (pathologists and oncologists), patient organizations, industry (diagnostic and drug developers), and others have supported the design and implementation of the Diagnostic Quality Assurance Pilot. The pilot helps to ensure that molecular diagnostics provide clinicians with consistent and correct answers, regardless of which lab conducts the test and which diagnostic platform the lab uses. In April of 2019, the pilot’s steering committee, which includes representatives from Friends of Cancer Research, the College of American Pathologists, Palmetto GBA, Blue Cross Blue Shield Association, Amgen, and others, along with liaisons from FDA, CMS, and NCI, will convene in Washington, DC to discuss the pilot’s results.
Specifically, the pilot has engineered and disseminated reference samples and a bioinformatics challenges for labs to assess whether their appropriately validated tests can achieve diagnostic performance comparable to an FDA-approved companion diagnostic (CDx). For the pilot, the test case at hand is a CDx for a targeted cancer therapy. The pilot aims to understand how this approach can better standardize and compare diagnostics used to select patients for targeted therapies in cancer treatment. During the April meeting, the pilot steering committee and representatives from its scientific technical working group will address the pilot’s outcomes, implications, and follow-on communications. For more background on the pilot, please visit the pilot’s website or Tapestry’s case study on the pilot’s implementation to date.
The European Corporate Governance Institute (ECGI), in a paper entitled Shareholder Collaboration published in August 2018, recently quoted Tapestry's work saying:
"Engagement does not just occur at the individual company level. Both investors and issuers are participating in a growing number of private initiatives aimed at promoting board-shareholder collaboration on a variety of issues and, in particular, corporate governance matters.
One of the first such initiatives was the “Shareholder-Director Exchange Program” (SDX), a private organization established in 2014 by representatives of major US corporations and big institutional investors like BlackRock and Vanguard. The SDX’s aim is promoting a voluntary template for healthy relations between shareholders and boards as well as regular and successful engagement on matters such as corporate governance, management changes, and long-term plans. Importantly, in defining successful engagement, the SDX’s protocol includes as essential “each party’s willingness to listen carefully to one another and to take action in response to valid concerns.” That is, each party’s willingness to collaborate with the other is seen as crucial within the SDX framework."